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Background: An inverse relation between chemotherapy-associated liver injury (CALI) and tumour
response to chemotherapy has been reported. The aim was to validate these findings, and further
investigate the impact of CALI on survival in patients who underwent partial hepatectomy for colorectal
liver metastases (CRLM).
Methods: Patients who received neoadjuvant chemotherapy and underwent partial hepatectomy for
CRLM between 2008 and 2014 were included. Liver and tumour specimens were histologically examined
for CALI (steatosis, steatohepatitis, sinusoidal dilatation [SD], nodular regeneration) and tumour
regression grade (TRG). TRG 1–2 was defined as complete tumour response.
Results: 166 consecutive patients were included with a median survival of 30 and 44 months for
recurrence-free and overall survival, respectively. Grade 2–3 SD was found in 44 (27%) and TRG 1–2
was observed in 33 (20%) patients. Of studied CALI, only grade 2–3 SD was associated with increased
TRG 3–5 (odds ratio 3.99, 95% CI 1.17–13.65, p = 0.027). CALI was not significantly related to survival.
TRG 1–2 was associated with prolonged recurrence-free (hazard ratio 0.47, 95% CI 0.25–0.89,
p = 0.020) and overall survival (hazard ratio 0.35, 95% CI 0.18–0.68, p = 0.002).
Conclusion: CALI was not directly related to survival. CALI was, however, associated with diminished
complete tumour response, and diminished complete tumour response, in turn, was associated with
decreased survival.Received 26 June 2017; accepted 31 August 2017Correspondence
StevenW.M. Olde Damink, Department of Surgery, Maastricht University Medical Centre, NUTRIM School
of Nutrition and Translational Research in Metabolism, Maastricht University, Universiteitssingel 50, 6229
ER Maastricht, The Netherlands. E-mail: steven.oldedamink@maastrichtuniversity.nlIntroduction
Neoadjuvant chemotherapy is used to downsize colorectal liver
metastases (CRLM) with the aim of facilitating future hepaticThe paper is not based on a previous communication to a society or
meeting.
HPB 2018, 20, 147–154 © 2017 International Hepato-Presection.1–3 Tumour downsizing relies on the tumour response
to chemotherapy, as expressed by the tumour regression grade
(TRG).4 CRLM patients with complete tumour response have
been shown to have better survival than those with poor
response.5
Systemic chemotherapy may have beneficial effects, but
frequently causes undesired liver parenchymal damage,ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
148 HPBcollectively referred to as chemotherapy-associated liver injury
(CALI). For instance, oxaliplatin-based treatment appears to be
related to the development of sinusoidal obstruction syn-
drome6–8 and nodular regeneration,9 whereas irinotecan-based
regimens are associated with increased occurrence of steatohe-
patitis.10–12 The authors have recently demonstrated that
chemotherapy-associated sinusoidal dilatation was related to
increased major morbidity, and therefore advised adaptation of
surgical management in case of its presence.8 Moreover, the
authors13 and others5 have previously shown that chemotherapy-
associated sinusoidal dilatation is associated with poor tumour
response to neoadjuvant chemotherapy.
Despite the significant inverse relation between CALI and
tumour response, few studies have examined the effect of CALI
on the long term survival of patients who undergo liver resection
for CRLM. Although one study claimed that chemotherapy-
associated sinusoidal dilatation was associated with shortened
survival,14 another study could not reproduce this.5 Therefore, it
remains unclear whether CALI influences survival. The first aim
of the present study was to validate the relation between CALI
and tumour response in an independent large cohort. The
second aim was to explore whether sinusoidal dilatation, nodular
regeneration, steatosis, and steatohepatitis were associated with
survival in CRLM patients after partial hepatectomy.Methods
Inclusion of patients
Consecutive patients who had undergone partial hepatectomy
for CRLM at Maastricht University Medical Centre between
January 2008 and December 2013 were considered for this study.
Inclusion criteria were: (i) patients treated with neoadjuvant
chemotherapy; (ii) availability of adequate histopathology
assessment of non-tumour bearing liver tissue (i.e. presence of
non-tumour-bearing liver at a distance of more than 2 cm from
the tumour). Patients with cirrhosis were excluded from the
study.
Definition and data collection
Comorbidity was defined as any disease affecting the patient
apart from colorectal liver metastases (e.g. diabetes mellitus, and
pulmonary, renal, cardiovascular, and other diseases). Overall
morbidity was defined as any complication occurring within 30
days after surgery or during hospital stay and graded according to
the classification of Dindo et al.15 Major morbidity was defined
as Dindo-Clavien score IIIa (requiring invasive intervention) or
higher. The concept of a liver surgery-specific complication was
in correspondence to the liver surgery-specific composite
endpoint (CEP) developed in 2011, and included one or more of
the following events: ascites, postoperative liver failure, bile
leakage, intra-abdominal abscess, intra-abdominal haemorrhage,
and operative mortality.16 90-day mortality rate was used as it
has been shown to be an equivalently specific measure ofHPB 2018, 20, 147–154 © 2017 International Hepato-Psurgery-related death and represents a legitimate measure of
surgical quality.17 Because postoperative infectious complica-
tions have been shown to be significant prognostic factors for
long-term survival after hepatectomy for colorectal liver metas-
tases,18 they were included as confounders when studying factors
related to survival in multivariable Cox regression models.
Postoperative infectious complications were prospectively
collected daily by an independent infection-control nurse based
on the following definitions, and defined as a combination of
surgical site infections,19 remote site infections, and systemic
sepsis. Radical resection was defined as resected tumour lesions
with a surgical margin of more than 1 mm, and confirmed to
have absent tumour cells on the margin from routine pathology
reports. With respect to tumour recurrence, patients were
followed up by monitoring blood levels of carcinoembryonic
antigen (CEA) every three months together with liver radiologic
imaging half-yearly in the first 2 years, and CEA half-yearly
together with liver radiologic imaging annually up to 5 years
after surgery. The date of last follow-up was November 2, 2016.
Pathology assessment of non-tumour-bearing liver
and metastases
Sinusoidal dilatation, nodular regeneration, steatosis, and
tumour regression grade were semi-quantitatively assessed by
two experienced liver pathologists (AW and CV). Diagnosis of
nodular regeneration was made only when confirming liver
fibrosis was absent or minor. Assessment of steatohepatitis was
performed by another experienced liver pathologist (JV) inde-
pendently. All pathologists were blinded to clinical information
concerning the patients.
The tissue was fixed in formalin, embedded in paraffin, and
stained with haematoxylin & eosin and reticulin. Sinusoidal
dilatation was graded according to Rubbia-Brandt et al.20
Nodular regeneration was graded according to the Wanless
scoring system.21 Steatosis was graded according to Kleiner
et al.22 Grade 2–3 liver injuries (i.e. sinusoidal dilatation, stea-
tosis, and nodular regeneration) were defined as severe lesions,
respectively. Patients presenting with at least grade 1 of each of
the three features (steatosis, hepatocellular ballooning, and
lobular inflammation) were classified as having steatohepatitis
according to the recently established SAF scoring system.23
Tumour regression was graded as described by Mandard et al.,4
for the assessment of tumour regression after preoperative
chemoradiotherapy for esophageal carcinoma, and modified for
liver metastases. Grade 1 is characterized by the absence of his-
tologically identifiable residual tumour and extensive fibrosis;
grade 2 shows the presence of rare residual tumour cells scattered
through the fibrosis; grade 3 represents a substantial amount of
residual tumour cells but fibrosis dominated; grade 4 reflects
residual tumour cells outgrowing fibrosis; and grade 5 indicates
the absence of any tumour regression. Tumour regression grade
1–2 was defined as complete tumour response, and grade 3–5
was defined as poor tumour response.ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Table 1 Clinical characteristics
Factors n [ 166
General characteristics
Gender (male) 103 (62%)
Agea (year) 65 (58–69)
Body mass indexa (kg/m2) 26 (24–28)
Comorbidity 106 (64%)
Portal venous embolization 9 (5%)
Primary colorectal tumour
Rectal cancer 72 (43%)
Tumour stages 3–4 (n = 165b) 144 (87%)
Lymph node with tumour cells (n = 162b) 113 (70%)
Liver metastases
Synchronous metastases (<12 months) 130 (78%)
a
HPB 149Statistical analyses
All statistical analyses were performed using IBM SPSS Statistics
for Windows (version 20.0). The relationship between CALI and
tumour regression grade was studied applying uni- and multi-
variable binary logistic regression models. Because portal venous
embolization (PVE) is known to provoke tumour progres-
sion,24,25 factors related to tumour regression grade were
analysed within the whole population as well as within those
patients that did not undergo PVE. Furthermore, the association
between CALI, tumour regression grade, infectious complica-
tions, and survival was analysed using uni- and multivariable
Cox regression models. Variables with p-value  0.10 in
univariable analysis were included in the multivariable analysis.
Odds ratios (OR) or hazard ratios (HR) with 95% confidence
intervals (CI) were calculated. A p-value  0.05 was considered
significant for all tests.Number of metastases 2 (1–3)
Diameter of largest metastasesa 3 (1–4)
CEA > 200 ng/ml at hepatectomy 5 (3%)
Chemotherapy details
5-Fluorouracil 6 (4%)
Oxaliplatin 153 (92%)
Capecitabine 152 (92%)
Irinotecan 8 (5%)
Bevacizumab 105 (63%)
Surgical details
Major hepatectomy (3 Couinaud segments) 78 (47%)
Pringle manoeuver 44 (27%)
Laparoscopic surgery 11 (7%)
Perioperative blood transfusion 32 (19%)
Radical resection 111 (67%)
Postoperative characteristics
Overall morbidity 76 (46%)
Major morbidity (Dindo-Clavien III–V) 29 (17%)
Liver surgery-specific complications 32 (19%)
Infectious complications 51 (31%)
Surgical site infections 41 (25%)
Remote site infections 26 (16%)
Ninety-day mortality 5 (3%)
Length of hospital staya (day) 8 (6–10)
CEA, carcinoembryonic antigen.
a Numeric variables are presented as median with inter quartile range.
b Due to missing data, indicated number of patients was below 166.Results
A total of 166 consecutive patients were included (Table 1).
Preoperative comorbidity was found in 106 (64%) patients,
including 13 (8%) diabetes, 70 (42%) cardiovascular, 18 (11%)
pulmonary, and 6 (4%) renal diseases. Ninety-nine (60%) pa-
tients had more than one liver metastasis. Capecitabine in
combination with oxaliplatin (CAPOX) was the most commonly
used regimen, which was administered to 152 (92%) patients.
Postoperative surgical site infections were present in 41 (25%)
patients, including 22 (13%) superficial wound, 6 (4%) deep
wound, and 27 (16%) intraabdominal organ/space infectious.
Remote site infections were found in 26 (16%) patients,
including 12 (7%) urinary tract and 15 (9%) respiratory tract,
and 6 (4%) central venous catheter-related infections.
Table 2 summarizes the pathology details of CALI. The impact
of CALI and other potentially important factors on tumour
regression grade is depicted in Fig. 1 (Detailed data are sum-
marized in Supplemental Table 1). Given the fact that only one
case of steatohepatitis was found, the relation between steato-
hepatitis and tumour regression grade could not be studied.
Severe sinusoidal dilatation was associated with increased
occurrence of diminished tumour response (OR 3.99, 95% CI
1.17–13.65, p = 0.027). An association between mild sinusoidal
dilatation and diminished tumour response was statistically not
significant (OR 2.38, 95% CI 0.83–6.85, p = 0.108). Addition of
bevacizumab to the chemotherapy treatment tended to be
associated with increased complete tumour response (OR 0.35,
95% CI 0.12–1.01, p = 0.052). Severe steatosis (OR 0.85, 95% CI
0.33–2.21, p = 0.741) and severe nodular regeneration (OR 1.88,
95% CI 0.39–9.12, p = 0.434) were not related to tumour
regression grade. The association between CALI and tumour
regression was also analysed in the subgroup of patients who did
not undergo PVE, and similar results were found (Supplemental
Table 1). In another subgroup analyses, an inverse relation be-
tween the addition of bevacizumab and occurrence of severeHPB 2018, 20, 147–154 © 2017 International Hepato-Psinusoidal dilatation (OR 0.35, 95% CI 0.17–0.76, p = 0.008) was
observed. Similarly, presence of severe steatosis was also inversely
related to that of severe sinusoidal dilatation (OR 0.23, 95% CI
0.08–0.66, p = 0.006) (Supplemental Table 2).
The relation between potential prognostic factors and
recurrence-free survival is summarized in Fig. 2 (Detailed data
are summarized in Supplemental Table 3). Until the date of lastancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Figure 1 Factors related to tumour response
Table 2 Pathology characteristics
Pathology details n [ 166
Sinusoidal dilatation
Absent 76 (46%)
Grade 1 46 (28%)
Grade 2 30 (18%)
Grade 3 14 (8%)
Nodular regeneration (n = 133a)
Absent 108 (65%)
Grade 1 11 (7%)
Grade 2 12 (7%)
Grade 3 2 (2%)
Steatosis
Absent 62 (37%)
Grade 1 56 (34%)
Grade 2 29 (17%)
Grade 3 19 (11%)
Steatohepatitis 1 (1%)
Tumour regression grade
Grade 1 20 (12%)
Grade 2 13 (8%)
Grade 3 47 (28%)
Grade 4 56 (34%)
Grade 5 30 (18%)
a Due to unavailable collagen staining, indicated number of patients was
below 166.
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150 HPBfollow-up, 97 (58%) patients developed recurrence. Median
recurrence-free survival was 30 months (95% CI 23–38
months). Both complete tumour response (HR 0.47, 95% CI
0.25–0.89, p = 0.020) and radical resection (HR 0.58, 95% CI
0.38–0.88, p = 0.011) were associated with prolonged
recurrence-free survival. The presence of remote site infections
was the sole factor independently related to shortened
recurrence-free survival (HR 1.87, 95% CI 1.06–3.30, p = 0.030).
Fig. 3 summarizes the association between potential prog-
nostic factors and overall survival (Detailed data are summarized
in Supplemental Table 4). Until the date of last follow-up, 65
(39%) patients were alive, and the rest deceased. Median overall
survival was 44 months (95% CI 36–52 months). Complete
tumour response (i.e. tumour regression grade 1–2, HR 0.35,
95% CI 0.18–0.68, p = 0.002) and radical resection (HR 0.52,
95% CI 0.34–0.80, p = 0.003) were associated with prolonged
overall survival. Synchronous (<12 months) liver metastases (HR
1.98, 95% CI 1.14–3.47, p = 0.016) and remote site infections
(HR 1.87, 95% CI 1.06–3.30, p = 0.030) were independently
related to shortened overall survival.Discussion
The data of the present study demonstrate that poor tumour
response after neoadjuvant chemotherapy occurred more often
in patients with sinusoidal dilatation, whereas neither steatosis
nor nodular regeneration was associated with tumour response.
Complete tumour response, in turn, was a strong independent
predictor of prolonged recurrence-free survival and overall sur-
vival. However, none of the studied background liverancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Figure 2 Prognostic factors related to recurrence-free survival
HPB 151abnormalities was independently related to survival. Addition of
bevacizumab to chemotherapy was associated with decreased
occurrence of sinusoidal dilatation, and tended to be related to
increased complete tumour response. Moreover, remote site in-
fections were related to reduced recurrence-free survival and
overall survival, whereas radical resection was associated with an
increase for these outcome parameters.
Although sinusoidal dilatation was associated with diminished
complete tumour response, which was associated with
recurrence-free survival and overall survival, sinusoidal dilata-
tion itself was not directly related to survival. As neoadjuvant
chemotherapy provides increased complete tumour response,26
and this is related to prolonged survival, this observation
might indicate that the benefits of neoadjuvant chemotherapy in
terms of prolonging survival outweigh the harm of
chemotherapy-induced undesired parenchymal liver injury. It is
also suggested that chemotherapy could be more beneficial if
clinicians could reduce the negative impact of CALI on tumour
response. Moreover, the absence of statistical significance of the
relationship between sinusoidal dilatation and survival could also
be due to a type II error. Therefore, future studies with larger
sample size are encouraged. Since addition of bevacizumab to the
chemotherapy treatment was associated with both a lower
prevalence of sinusoidal dilatation and a tendency to increasedHPB 2018, 20, 147–154 © 2017 International Hepato-Ptumour response, it seems beneficial to add bevacizumab to
oxaliplatin-based chemotherapy.27
In the present study, the previously shown5,13 inverse relation
between chemotherapy-associated sinusoidal dilatation and
tumour regression grade was confirmed. There may be several
explanations for this finding. Loss of fenestrae in sinusoidal
endothelial cells, which has been shown in an animal model of
sinusoidal obstruction syndrome,28 might inhibit the transport
of compounds29 such as oxaliplatin to the tumour, thereby
limiting chemotherapy exposure. Oxaliplatin based chemo-
therapy is also known to lead to the detachment of sinusoidal
endothelial cells from the space of Disse,30 which may further
weaken the hepatic microcirculation and limit transportation of
drugs to the tumour.30,31 Moreover, a compromised hepatic
microcirculation will lead to hypoperfusion and may induce a
state of hepatic hypoxia.32 Tumour hypoxia will subsequently
stimulate angiogenesis that may promote tumour cell invasion.33
Taken together, loss of fenestrae from sinusoidal endothelial cells,
a weakened hepatic microcirculation, and hepatic hypoxia
related to sinusoidal dilatation are all potential contributors to a
diminished tumour response.
In line with a previous report,18 the present study shows a
negative relation between the presence of remote site infections
and recurrence-free survival as well as overall survival. Althoughancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Figure 3 Prognostic factors related to overall survival
152 HPBthe mechanisms underlying this observation remain unclear, and
a specific cause–effect relationship cannot be proven, the innate
or adaptive immunity may play an important role.
Some limitations of this study should be discussed. Although
analysis of the effect of steatohepatitis on tumour regression
grade and survival would have been of interest, this was not
possible since only one patient was diagnosed with steatohepa-
titis. This very low incidence of steatohepatitis could be due to
the fact that only a small number of patients were treated with
irinotecan, a known risk factor for the development of steato-
hepatitis.10–12 Next, data on the interval between cessation of
neoadjuvant chemotherapy and partial hepatectomy, as well as
the number of administered cycles, were not available for the
majority of included patients, since chemotherapy was frequently
administered at local referral hospitals. Therefore, the influence
of these factors on tumour regression grade and survival could
not be evaluated. Additionally, this study could not clarify
whether patients with the lowest tumour responsiveness received
continuous chemotherapy and therefore had an increased sinu-
soidal dilatation severity. Moreover, it could not identify whether
patients who developed sinusoidal dilatation did not undergo
partial hepatectomy at a later point, which could be associatedHPB 2018, 20, 147–154 © 2017 International Hepato-Pwith worse tumour pathologic evaluations. Because data on
chemotherapy cycles and doses, as well as intervals between
cessation of chemotherapy and surgery was lacking, we were not
able to investigate whether patients with comorbidity and
diminished tumour response received reduced cycles or doses of
chemotherapy, which might underlie the observation that the
presence of comorbidity was negatively related to tumour
response. Despite this limitation, it must be highlighted that the
majority of the studied population received the same regimen,
which was capecitabine in combination with oxaliplatin.
Therefore, the effect of treatment regimen related factors on
tumour regression grade and survival was presumably minimal.Conclusion
This study demonstrated that chemotherapy-associated sinu-
soidal dilatation is related to diminished complete tumour
response after neoadjuvant chemotherapy. Complete tumour
response was shown to be the strongest predictor of prolonged
recurrence-free survival and overall survival. None of the back-
ground parenchymal chemotherapy-induced liver injuries were
associated with survival. Addition of bevacizumab was associatedancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
HPB 153with decreased sinusoidal dilatation, and tended to be related to
increased complete tumour response.
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